BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Business > article

Samsung BioLogics wins $314 mln CMO deal from unnamed European client

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : June 24, 2020, 12:48 | Updated : June 24, 2020, 12:48
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of Samsung Biologics]



SEOUL -- Samsung BioLogics, a leading bio company in South Korea, has clinched a deal worth $314 million from an unnamed European client for the consignment production of a biosimilar drug. It accounted for 54.3 percent of the company's total sales estimated at $583.8 million last year.

Samsung BioLogics said in a regulatory filing that it has signed a letter of intent on contract manufacturing organization (CMO), which serves other companies in the pharmaceutical industry to provide comprehensive services from development through manufacturing. The biosimilar will be produced at a plant run by Samsung BioLogics in Songdo, a business zone in the western port city of Incheon.

Details such as the name of the European client will be disclosed after December 31, 2023. With the new deal, Samsung Biologics' accumulated orders for the first half of this year stood at 1.76 trillion won. U.S.-based pharmaceutical companies accounted for 62.1 percent of the total.

Samsung BioLogics has expanded its biomedicine business from to contract development organization (CDO), which develops cell lines and production processes for the mass production of antibody-drug candidate substances developed at the laboratory level.

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .​Samsung Biologics forges strategic partnership with Chinas GeneQuantum.
    ​Samsung Biologics forges strategic partnership with China's…
  • .Genexine works with domestic company to develop antibody treatment.
    Genexine works with domestic company to develop antibody tre…
  • .Samsung BioLogics makes $1.47 bln investment to build fourth plant.
    Samsung BioLogics makes $1.47 bln investment to build fourth…
  • .Samsung Bioepis demonstrates efficacy of first biosimilar for eye disease treatment.
    Samsung Bioepis demonstrates efficacy of first biosimilar fo…

Real Time Photo News

  • .Singer HyunA to end 14-month hiatus with mini-album Im Not Cool.

    Singer HyunA to end 14-month hiatus with mini-album 'I'm Not Cool'

  • .NCSofts global K-pop fan community platform to service original content including songs.

    NCSoft's global K-pop fan community platform to service original content including songs

  • .Singer IU drops teaser image for upcoming full album.

    Singer IU drops teaser image for upcoming full album

  • .Cube Entertainment partners with web comics company to create online video content.

    Cube Entertainment partners with web comics company to create online video content

  • .Sci-fi film starring Song Joong-ki to be reelased on Netflix in February.

    Sci-fi film starring Song Joong-ki to be reelased on Netflix in February

Latest News

more+

  • KHNP localizes new CIGS solar cells for building integrated photovoltaic system
  • Hyundai tests autonomous robot assistant in Seoul showroom
  • Exports of Korean chili paste up sharply thanks to growing popularity of K-drama
  • LG Innotek develops compact digital car key module for enhanced security and accuracy
  • KT unveils app for collecting COVID-19 research data
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view